DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for oculocutaneous albinism type 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOculocutaneous albinism type 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oculocutaneous albinism type 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Albinism is a group of inherited disorders caused by mutations in genes that reduce or eliminate melanin pigment biosynthesis. As of 2025, 22 genes have been identified across various forms of the condition. The phenotypic spectrum is broad, including hypopigmentation of skin, hair, and eyes; optic track misrouting; foveal hypoplasia; and reduced visual acuity. In a 2018 study of six albinism families, genetic sequencing identified pathogenic variants in four probands: two compound heterozygous mutations in the TYR and OCA2 genes (associated with OCA1 and OCA2), and two hemizygous mutations in the GPR143 gene (associated with OA1). Five of these mutations were novel. In one case, the clinical phenotype suggested oculocutaneous albinism but genetic diagnosis revealed ocular albinism type 1, indicating that molecular analysis is important for accurate diagnosis.
A 2025 scoping review focused specifically on therapeutic interventions for visual deficits in adults with oculocutaneous albinism and ocular albinism, using studies from the past 15 years. The review aimed to map existing evidence on medical, surgical, and supportive therapies, and to identify gaps in knowledge. No specific results from that review are reported in the abstract.
As of 2023, there is no specific treatment for albinism. Management remains palliative, consisting of vision correction and recommendations for sun behaviour and skin protection to reduce complications. A 2025 review states that emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies, but no clinical trial results are reported. No drug is named in any of the abstracts as having been tested in patients with oculocutaneous albinism type 3 specifically.
What is still missing are clinical trials in patients, funding for translational research, and any evidence that repurposed drugs improve visual function or pigmentation in humans. The preclinical promise noted in one review has not yet been tested in controlled human studies, and no patient stratification strategy has been validated for any candidate therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the European Academy of Dermatology and Venereology · 2003 · 75 citations
Oculocutaneous albinism
AbstractOculocutaneous albinism represents a group of inherited skin disorders characterized by a generalized reduction of cutaneous, ocular and pilar pigmentation from the time of birth. Oculocutaneous albinism types 1 and 2 are the most common, but several other types have been described. A defect in the melanin synthesis pathway, resulting in reduced formation of melanin, is responsible for oculocutaneous albinism. Aetiology, clinical manifestations, diagnosis and management are discussed.
Current Opinion in Pediatrics · 1999 · 37 citations
Albinism
AbstractAlbinism was one of the first genetic diseases to be noted in humans, but until relatively recently, little was known of the molecular mechanisms involved in its pathogenesis. Recent advances have shown us that mutations in at least seven different genes can cause a reduction in melanin pigment biosynthesis, producing the various associated clinical features associated with albinism, including hypopigmentation of the skin, hair, and eyes; optic track misrouting; foveal hypoplasia; and reduced visual acuity. Analysis of mutations in these seven genes has revealed that the phenotypic spectrum associated with albinism is broad, making molecular analysis an important part in the accurate diagnosis of this disease.
Compound Heterozygous Mutations in 2 Siblings with Hermansky-Pudlak Syndrome Type 1 (HPS1)
AbstractBACKGROUND: Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder causing oculocutaneous albinism, bleeding disorder and ceroid lipofuscinosis. Platelets from HPS patients are characterized by the absence of dense (delta)-bodies. There are eight known human HPS GENES (HPS1-HPS8), each leading to a particular clinical HPS subtype. Restrictive lung disease, granulomatous colitis and cardiomyopathy have been described in HPS1 patients. PATIENTS: We identified HPS1 in Russian and in German siblings. All four patients show a typical HPS phenotype. The two older Russian patients demonstrate excessive bleeding after tooth extractions, recurrent epistaxis and hematomas. The two younger German patients suffer only from hematomas, so far. METHODS/RESULTS: Patients' platelets showed severe pathological agglutination/aggregation. Flow cytometry analysis demonstrated absence of platelet delta-granule secretion. Three different mutations in the HPS1 gene were found in the two families. Two mutations, p.H119delC and p.Q397delC identified in the Russian siblings had been previously described. The German siblings presented with a novel frameshift mutation (p.Q32_S33delCAGT) and the known p.Q397delC mutation. CONCLUSION: Patients with oculocutaneous albinism should be investigated for increased clinical bleeding symptoms. In case of increased bleeding symptoms, analyses of primary hemostasis should be initiated to confirm HPS. Molecular genetic investigations should be performed to distinguish the different subtypes of HPS which is important for therapy and prognosis.
Open Science Framework · 2025 · 0 citations · open access
Visualizing Progress: A Scoping Review of Therapeutic Interventions for Ocular and Oculocutaneous Albinism
AbstractThis scoping review is focused on identifying and mapping the existing evidence on medical, surgical, and supportive therapies studied in adults with Oculocutaneous Albinism (OCA) and Ocular Albinism (OA). Studies published in the past 15 years will be utilized to provide an updated overview of current and emerging treatments, determine gaps in knowledge, and inform future research directions. While previous reviews have focused on both dermatologic and visual symptoms experienced by patients with albinism, our review solely centers on the efficacy of treatments for visual deficits. We believe a more thorough review focusing on improvements of visual deficits will provide a clinically relevant perspective for healthcare providers and researchers.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
ALBINISM DISEASE - CLASSIFICATION, DIAGNOSIS, SYMPTOMS AND TREATMENT MEASURES
AbstractAlbinism is a group of hereditary pathologies characterized by a violation or complete absence of skin, hair, eye pigmentation. The main symptoms of the disease are very pale skin and hair, blue or red eyes, and in some cases, vision impairment. The diagnosis of albinism is made based on the current condition of the patient, as well as genetic tests. To date, there is no specific treatment for albinism, palliative therapy (correction of vision) is used, and there are a number of recommendations for patients to behave in the sun, protect the skin and reduce the likelihood of complications
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
ALBINISM DISEASE - CLASSIFICATION, DIAGNOSIS, SYMPTOMS AND TREATMENT MEASURES
AbstractAlbinism is a group of hereditary pathologies characterized by a violation or complete absence of skin, hair, eye pigmentation. The main symptoms of the disease are very pale skin and hair, blue or red eyes, and in some cases, vision impairment. The diagnosis of albinism is made based on the current condition of the patient, as well as genetic tests. To date, there is no specific treatment for albinism, palliative therapy (correction of vision) is used, and there are a number of recommendations for patients to behave in the sun, protect the skin and reduce the likelihood of complications
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ALBINISM- A CONGENITAL DISORDER
AbstractABSTRACT Background: Albinism encompasses a group of inherited disorders characterized by reduced or absent melanin biosynthesis, affecting approximately 1 in 20,000 individuals worldwide with significant variability across geographical regions. These conditions present substantial clinical challenges and impact quality of life. Objective: This review aims to synthesize current understanding of albinism's genetic mechanisms, clinical manifestations, diagnostic approaches, available treatments, and emerging therapeutic strategies to provide a comprehensive framework for clinicians and researchers. Methods: A systematic literature search was conducted using PubMed, EMBASE, and Web of Science databases for articles published between 2000-2024, using keywords including "albinism," "oculocutaneous albinism," "ocular albinism," "melanin biosynthesis," "tyrosinase," and "albinism treatment." Studies were selected based on relevance, methodological rigor, and contribution to understanding albinism pathophysiology or treatment. Results: Recent advances have expanded understanding of albinism's genetic basis, with 22 genes now identified across various forms. Comprehensive phenotypic characterization has refined diagnostic approaches, while emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies. Conclusion: Albinism represents a paradigm for understanding melanin biology and neurodevelopmental visual pathways. While current management remains supportive, emerging molecular-based therapies may offer disease-modifying potential. Multidisciplinary approaches and increased awareness are essential to address both medical and psychosocial aspects of these conditions.
Pathogenic gene screening and phenotypic analysis of six albinism families
AbstractObjective
To analyze the pathogenic gene types and phenotypic characteristics of 6 albinism families.
Methods
A retrospective series of case studies. Six probands of albinism and 20 family members were recruited for this study, 5 probands with clinical manifestations of oculocutaneous albinism (OCA) and 1 proband of ocular albinism (OA). Genomic DNA was extracted from peripheral venous blood which was collected from 6 probands and 20 family members. Genetic variations were screened by whole-exome sequencing or Sanger sequencing and then analyzed the relationship between genotypes and phenotypes.
Results
Genetic sequencing identified 6 potential pathogenic variants in 4 probands, including 2 compound heterozygous mutations in the 2 genes [TYR (c.1037-7T> A, c.925_c.926insC), OCA2 (c.2359G> A, c.587T> C)] associated with OCA1 and OCA2, and 2 hemizygous mutations in the GPR143[GPR143 (c.11C> G), GPR143 (c.333G> A)] associated with OA1, respectively. In which, 5 were novel mutations and confirmed by Sanger sequencing. One case was accorded with OCA in clinical phenotype, but genetic diagnosis was OA1, the others were agreement between clinical diagnosis and genetic diagnosis.
Conclusion
There are 4 families with mutations in 6 families, representative of 3 type of albinism (OCA1, OCA2, OA1).
Key words:
Albinism, oculocutaneous/genetics; GPR143 gene; Heterozygote; Mutation
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
